Recent News
Read ArticleThe last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented.
INDIGO: Switching B Cells Off, Not Out, in IgG4-Related Disease
B-cell targeting has moved to the centre of IgG4-related disease treatment, with inebilizumab, a CD19 depleter, as the recent benchmark. At EULAR 2026, INDIGO tested whether the disease can be controlled by switching B cells off rather than depleting them.
Read Article
RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest
At EULAR 2026, speakers of the session “Catching Your Breath: Unravelling RA Associated Interstitial Lung Disease (ILD)” noted RA-ILD is one of the few outcomes not improving in the biologic era. Three abstracts reinforce that message and make the case for a practical, low-cost screening tool that is already in most rheumatologists’ hands.
Read Article
Some new #vaccination #recommendations
#EULAR2026
@RheumNow https://t.co/j7cOJPpOcV https://t.co/VnGkFwTZ86
Links:
Janet Pope @Janetbirdope ( View Tweet)
Remember
Babies of pts on chronic #immunosuppression with #SARDs
❎delay #vaccinations til 6/12
For safety & to mount sufficient response
#rotovirus #vaccine is Ok before 6 months or vaccine is ineffective
Pts w #SARDs need #COVID shots
@RheumNow #EULAR2026 #vaccine #recom https://t.co/WEzNajWlxY
Links:
Janet Pope @Janetbirdope ( View Tweet)
What’s new with the 2026 update of reco for vax in AIIRD?
Vaccinate as soon as possible
Non-live vaccines are safe
Hold MTX for upto 2wks to inc vax yield
Strong reco for RZV
Catch-up vax for HPV in SLE
Rotavirus vax for newborns exposed in utero to TNFi
@RheumNow #EULAR2026 https://t.co/RZbyvAcYRI
Links:
sheila @RHEUMarampa ( View Tweet)
#EULAR2026 #SARD #vaccination #recommendations
I think 🤔
✅proactive➡️take responsibility
✅close gap
✅mostly practical
But
How long will #shingrix work if #vaccine
In age<50yrs
When if ever
To revaccinate?
@RheumNow @eular_org @ACRheum https://t.co/najJwzdecL
Links:
Janet Pope @Janetbirdope ( View Tweet)
#OP0156 #EULAR2026 FT839, CART therapy targeting CD19 & CD38, showed potent depletion of pathogenic B cells, plasmablasts/plasma cells & activated T cells, w/o conditioning chemotherapy. Data suggest potentially more accessible CART approach across autoimmune diseases. @RheumNow https://t.co/9COyXbghkl
Mrinalini Dey @DrMiniDey ( View Tweet)
Updated SLR on D2T #RA (131 studies): JAKi maintain ACR20 even after 2-3 prior bDMARDs, with UPA outperforming ABA in head-to-head. But evidence on non-pharmacologic strategies in D2T RA remains nearly absent. Clear gap for future trials. @RheumNow #EULAR2026 POS1246
Jiha Lee @JihaRheum ( View Tweet)
Good performance of #definite
#antisynthetase #syndrome
✅+antibody mandatory
Possible also does ok
@RheumNow #EULAR2026
June 6 #antisynthetase #classifiaction #criteria https://t.co/5sxogTX9YT
Links:
Janet Pope @Janetbirdope ( View Tweet)
Steroid use remain common in rheumatology, despite risks even low-dose, especially for older adults.
"Steroids and Me" (Sam) provides online patient education ~5 minutes.
@RheumNow #EULAR2026 POS1388
Jiha Lee @JihaRheum ( View Tweet)
Dr. Cavagna presents the 2025 EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome
He emphasizes the inportance of ruling out anti-MDA5 Ab & anti-PM/Scl Ab DM since these conditions share overlapping features w/ ASyS.
@RheumNow #EULAR2026 https://t.co/AtGRlp5qyW
Links:
sheila @RHEUMarampa ( View Tweet)
#OP0159 #EULAR2026
Multimodal study in D2T RA identified altered brain connectivity patterns linked to pain, psychological features & peripheral transcriptomics. Supports neuroimmune component in D2T RA & need for personalised approaches beyond inflammation control. @RheumNow https://t.co/qMQbkiMCwX
Mrinalini Dey @DrMiniDey ( View Tweet)
Does #RA accelerate age-related functional decline in older adults? STAR study (n=421, age 55-85): RA with worse HAQ, grip strength, but aging's effect on function similar in RA vs controls. Geriatric syndromes like sarcopenia may matter more than RA @RheumNow #EULAR2026 POS0360
Jiha Lee @JihaRheum ( View Tweet)
Thoracic U/S for #RA-ILD screening? Multicenter study (n=272, Argentina/Denmark/Belgium): 86% sensitivity and 94% NPV. Accessible, no radiation, integrates into clinic flow. Time to build TUS into routine RA-ILD pathways? @RheumNow #EULAR2026 POS1265 https://t.co/FGH5iUstxa
Jiha Lee @JihaRheum ( View Tweet)
Think palindromic rheumatism is non-erosive? Not always. Leeds U/S cohort (n=127, 16yrs follow-up): 9.4% had low-grade erosions at baseline; 6.1% without baseline erosions developed new erosions over 53 mo. More frequent flares, more erosions. @RheumNow #EULAR2026 POS1262
Jiha Lee @JihaRheum ( View Tweet)
Patient-initiated telemedicine follow-up cut rheumatology visits by 25% in stable #SpA, but not equally for everyone. Reductions were greatest in men, axSpA, bDMARD users, and the oldest patients (64+, 34% fewer visits). Patient-centered care delivery @RheumNow #EULAR2026 POS1345
Jiha Lee @JihaRheum ( View Tweet)
T2T works in elderly-onset #RA. tREACH trial (n=425): EORA (mean age 73) achieve LDA similar to young-onset RA; often with lower treatment intensity when seronegative. Drug tolerability comparable in EORA vs YORA despite more comorbidities. @RheumNow #EULAR2026 POS1326 https://t.co/tKRki2KLzP
Jiha Lee @JihaRheum ( View Tweet)
Do u screen your SLE pts for OP?
In this real-world multicenter study, SLE pts who were likely to be tested for BMD were older, had MSK s/sxs, sSJg & longer GC exposure.
RFs for OP: LN, higher dse. activity, longer GC use, high cumulative GC dose
POS1372 @RheumNow #EULAR2026 https://t.co/pAxhOPGGYs
sheila @RHEUMarampa ( View Tweet)
SELECT-Axis 2 trial and Withdrawal of Upadacitinib - Of 734 pts, 194 were in remission at wk104--> UPA w/d & 22% maintained drug-free remission for >48wks. Rest flared, median time to flare: 3.1 mos (89% regained LDA by wk24 w/ restart) #EULAR2026 #axSpA POS1350 https://t.co/7A7CAHxLxX
Dr. John Cush @RheumNow ( View Tweet)
From the Blog
Podcasts
Day 4 Recap EULAR 2026
EULAR 2026 Daily Podcast Day 3a
day3recap-
EULAR 2026 Daily Podcast Day 2c
Therapeutic Updates
Psoriatic arthritis and overweight or obesity
Sponsored by Lilly Medical Affairs
Dr. Merola presenting the results from TOGETHER‑PsA, a phase 3b trial evaluating the concomitant use of an IL‑17A antagonist and an incretin receptor agonist in adults with psoriatic arthritis and overweight or obesity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
